dabigatran Tagged Articles
Did Boehringer Ingelheim withhold safety information about blood thinner Pradaxa?
When Pradaxa (dabigatran) hit the market in 2010 to prevent strokes in patients with atrial fibrillation, it became the first alternative treatment to the long-used warfarin for patients with the condition. What made Pradaxa so attractive compared to warfarin (Coumadin)
Boehringer Ingelheim to pay $650 million to resolve Pradaxa lawsuits
Boehringer Ingelheim announced it will pay $650 million to resolve about 4,000 state and federal lawsuits alleging the company’s blood thinner Pradaxa caused patients to suffer serious bleeding events.
Increased risk of stroke in patients at start of warfarin treatment
Patients with a common irregular heart rhythm known as atrial fibrillation are typically put on blood thinners, such as the long-prescribed warfarin, to help prevent strokes caused by blood clots. However, patients are especially vulnerable to stroke when they first start
New black box warning added to blood thinner Pradaxa
Stopping treatment of the blood thinner Pradaxa (dabigatran) increases the risk of stroke, according to a new black box warning placed on the drug’s label. Pradaxa is an anticoagulant that was approved in 2010 for the prevention of strokes in
Officials offer theories why Pradaxa associated with so many bleeding events
Theories abound as to why bleeding risks with the blood thinner Pradaxa (dabigatran) appear greater than the long-used Coumadin (warfarin). In a perspective published online in the New England Journal of Medicine, Food and Drug Administration (FDA) officials speculate the
Atrial fibrillation patients should be aware of risks associated with Pradaxa vs. Warfarin
Anticoagulants are often given to patients with a type of heart rhythm abnormality known as atrial fibrillation to prevent strokes. The reasoning is that in people with atrial fibrillation, the upper chambers of the heart pump abnormally causing blood to
Antidote in development for new blood thinners Xarelto, Eliquis
Four drug companies have signed on to fund Protola Pharmaceuticals’ experimental antidote for reversing the effect of Factor Xa inhibitor drugs, blood thinners that block the activity of clotting Factor Xa and prevent blood clots from developing or getting worse.
Anti-clotting drug Eliquis gets FDA approval
Eliquis, a new anti-clotting drug developed by Bristol-Myers Squibb and Pfizer as an alternative to the decades-old warfarin (Coumadin), has finally won approval from the U.S. Food and Drug Administration (FDA).